BioRender Icon

Oligodendrocyte (pre-myelinating)

Oligodendrocyte (pre-myelinating) - Editable icon of an inactivated oligodendrocyte before attachment to axon for myelination
[{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458340/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458340/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458341/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458341/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458342/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458342/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458343/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458343/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458344/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458344/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458345/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458345/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458346/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458346/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458347/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458347/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458348/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458348/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458349/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458349/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834a/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834a/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834b/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834b/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834c/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834c/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834d/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834d/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834e/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834e/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845834f/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845834f/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458350/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458350/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458351/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458351/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458352/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458352/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458353/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458353/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458354/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458354/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458355/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458355/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458356/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458356/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458357/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458357/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458358/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458358/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458359/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458359/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835a/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835a/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835b/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835b/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835c/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835c/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835d/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835d/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835e/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835e/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845835f/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845835f/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458360/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458360/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458361/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458361/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458362/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458362/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458363/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458363/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458364/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458364/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458365/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458365/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458366/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458366/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458367/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458367/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458368/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458368/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458369/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458369/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836a/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836a/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836b/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836b/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836c/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836c/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836d/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836d/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836e/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836e/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba1845836f/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba1845836f/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458370/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458370/5a7cc6a90d495d001444bc2d.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66e20227bbcd5bba18458371/5a7cc6a90d495d001444bc2d.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66e20227bbcd5bba18458371/5a7cc6a90d495d001444bc2d.png"}]
Use This Icon – Free
No credit card required to sign up.

This icon is fully editable in BioRender

  • Add text, shapes, & other icons
  • Search 50,000+ scientifically accurate icons
  • Recolor and rearrange every icon, line, & label
  • Export or share for any use case
Scientist Avatars

Join 4M+ scientists already making publication-ready figures

Go from icons to finished figure – in minutes

  • Search from 50,000+ scientifically accurate, peer-reviewed icons
  • Customize with labels, shapes, and additional icons – everything is completely editable
  • Export or share your figures with collaborators

Not quite the right template? Discover more.

Search thousands of templates across 30+ life-science fields.

search icon
arrow-right
Keywords
oligodendrocyte,oiigodendroglia,glial cell,myelin,myelination,neuron,neuroglia,pns,peripheral nervous system,axon,pre-myelinating oligodendrocyte,PMO
View More

Try a synonym, or sign up to request an icon from the app.

Image types

Oligodendrocyte (pre-myelinating) icon JPEG

Oligodendrocyte (pre-myelinating) icon PNG

Oligodendrocyte (pre-myelinating) icon SVG

Oligodendrocyte (pre-myelinating) icon GIF

Biorender Icon FAQs

How are scientists using the Oligodendrocyte (pre-myelinating) icon in their work?

BioRender users often use the Oligodendrocyte (pre-myelinating) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

Can I use this icon in a BioRender figure or scientific illustration?

Yes, the Oligodendrocyte (pre-myelinating) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Oligodendrocyte (pre-myelinating) icon customizable in BioRender?

Most icons in BioRender, including the Oligodendrocyte (pre-myelinating) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Oligodendrocyte (pre-myelinating) icon for publication or presentations?

Yes, figures containing the Oligodendrocyte (pre-myelinating) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Oligodendrocyte (pre-myelinating) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Oligodendrocyte (pre-myelinating) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

What is BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Oligodendrocyte (pre-myelinating) icon along with our library of more than 30,000 life science icons.

Looking for science content?

Browse 50K+ icons and templates that are peer-reviewed, easy to use, and free.

Find yours now
x icon